Results 221 to 230 of about 1,510,006 (306)
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley +1 more source
Health service utilization and medical costs for in-hospital death at the end of life. [PDF]
Duan S +8 more
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Supportive environments moderate the relationship between frailty and life satisfaction in older adults: evidence from the China health and retirement longitudinal study (CHARLS). [PDF]
Chao KK, Che SL, Wong KK.
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Adverse childhood experiences and late-life depression in older Chinese adults: the mediating roles of sleep disorders and chronic diseases. [PDF]
Li Q, Chen L, Wang R.
europepmc +1 more source
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
The Postal Life Insurance including dental services in Taiwan during the Japanese colonial period
Feng-Chou Cheng +2 more
doaj +1 more source
Sepsis in a Patient With Atopic Dermatitis Following Upadacitinib Discontinuation. [PDF]
Gallagher JA +3 more
europepmc +1 more source

